What is Ir-Med Inc's earnings per share (EPS)?

Ir-Med Inc (IRME) reported diluted earnings per share of $-0.03 for fiscal year 2024. This represents a 57.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ir-Med Inc Financials

IRME

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE December

This page shows Ir-Med Inc (IRME) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 11/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Ir-Med Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Ir-Med Inc carries a low D/E ratio of -1.85, meaning only $-1.85 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 67/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Ir-Med Inc's current ratio of 0.38 is below the typical benchmark, resulting in a score of 2/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.03

YoY+57.1%

Ir-Med Inc earned $-0.03 per diluted share (EPS) in fiscal year 2024. This represents an increase of 57.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$129K

YoY-83.2%

Ir-Med Inc held $129K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

71M

YoY+1.5%

Ir-Med Inc had 71M shares outstanding in fiscal year 2024. This represents an increase of 1.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$710K

YoY-65.6%

Ir-Med Inc invested $710K in research and development in fiscal year 2024. This represents a decrease of 65.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

IRME Income Statement

Metric	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$710K-65.6%	$2.1M+9.3%	$1.9M+32.8%	$1.4M+246.9%	$409K
SG&A Expenses	$1.0M-50.1%	$2.0M-4.2%	$2.1M+54.8%	$1.4M+326.2%	$321K
Operating Income	N/A	-$4.9M-3.1%	-$4.8M-29.6%	-$3.7M-403.4%	-$730K
Interest Expense	-$3K-115.0%	$20K+433.3%	-$6K	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$4.9M-3.7%	-$4.7M-27.4%	-$3.7M-394.1%	-$752K
EPS (Diluted)	$-0.03+57.1%	$-0.070.0%	$-0.07	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$91K+295.7%	$23K	N/A	$205K+118.1%	$94K-51.8%	$195K	N/A	$469K
SG&A Expenses	$194K-14.9%	$228K	N/A	$367K+55.5%	$236K-20.0%	$295K	N/A	$431K
Operating Income	-$286K-13.0%	-$253K	N/A	-$601K-67.9%	-$358K+45.6%	-$658K	N/A	-$1.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$701K	N/A	N/A	-$598K-63.4%	-$366K+44.3%	-$657K	N/A	-$1.2M
EPS (Diluted)	$-0.010.0%	$-0.01	N/A	$-0.010.0%	$-0.010.0%	$-0.01	N/A	$-0.02

IRME Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20
Total Assets	$251K-74.9%	$999K-69.7%	$3.3M+11.9%	$2.9M+40.8%	$2.1M
Current Assets	$205K-75.8%	$848K-72.3%	$3.1M+6.1%	$2.9M+38.3%	$2.1M
Cash & Equivalents	$129K-83.2%	$767K-74.5%	$3.0M+6.6%	$2.8M+50.9%	$1.9M
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$76K-6.2%	$81K+47.3%	$55K-17.9%	$67K-69.3%	$218K
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$545K-14.0%	$634K-9.7%	$702K-76.1%	$2.9M+326.8%	$689K
Current Liabilities	$545K+15.2%	$473K-28.5%	$662K+67.6%	$395K	N/A
Long-Term Debt	N/A	N/A	$40K	N/A	N/A
Total Equity	-$294K-180.5%	$365K-85.9%	$2.6M+109221.0%	$2K-99.8%	$1.4M
Retained Earnings	-$16.7M-12.8%	-$14.8M-49.4%	-$9.9M-91.1%	-$5.2M-251.1%	-$1.5M

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$175K+41.1%	$124K-50.6%	$251K-52.9%	$533K-39.9%	$887K+53.2%	$579K-42.0%	$999K-43.7%	$1.8M
Current Assets	$90K+11.1%	$81K-60.5%	$205K-53.7%	$443K-43.9%	$789K+70.4%	$463K-45.4%	$848K-47.2%	$1.6M
Cash & Equivalents	$63K+23.5%	$51K-60.5%	$129K-67.1%	$392K-47.9%	$753K+84.6%	$408K-46.8%	$767K-49.7%	$1.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$27K-10.0%	$30K-60.5%	$76K+49.0%	$51K+41.7%	$36K-34.5%	$55K-32.1%	$81K-2.4%	$83K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$800K+29.7%	$617K+13.2%	$545K+2.6%	$531K+1.3%	$524K-21.2%	$665K+4.9%	$634K+13.0%	$561K
Current Liabilities	$774K+25.4%	$617K+13.2%	$545K	N/A	N/A	N/A	$473K-15.4%	$559K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$625K-26.8%	-$493K-67.7%	-$294K-14800.0%	$2K-99.4%	$363K+522.1%	-$86K-123.6%	$365K-69.9%	$1.2M
Retained Earnings	-$18.2M-4.0%	-$17.5M-4.6%	-$16.7M-1.7%	-$16.5M-3.8%	-$15.9M-2.4%	-$15.5M-4.4%	-$14.8M-9.4%	-$13.6M

IRME Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	N/A	-$3.2M+4.2%	-$3.4M-36.0%	-$2.5M-517.4%	-$402K
Capital Expenditures	N/A	$2K-96.0%	$50K+61.3%	$31K	N/A
Free Cash Flow	N/A	-$3.2M+5.6%	-$3.4M-36.3%	-$2.5M	N/A
Investing Cash Flow	N/A	-$2K+96.6%	-$59K+3.3%	-$61K	N/A
Financing Cash Flow	$750K-25.0%	$1.0M-72.4%	$3.6M+3.8%	$3.5M+71.5%	$2.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$71K+35.5%	-$110K+57.9%	-$261K+33.9%	-$395K-6.2%	-$372K-3.9%	-$358K+52.5%	-$754K+7.0%	-$811K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$1K	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$755K	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$1K	N/A
Financing Cash Flow	$88K+183.9%	$31K	$0-100.0%	$35K	N/A	N/A	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IRME Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-1344.9%-1162.3pp	-182.6%+156544.5pp	-156727.1%-156673.4pp	-53.7%
Return on Assets	N/A	-491.4%-347.7pp	-143.7%-17.5pp	-126.3%-90.3pp	-36.0%
Current Ratio	0.38-1.4	1.79-2.8	4.62-2.7	7.30	N/A
Debt-to-Equity	-1.85-3.6	1.74+1.7	0.02-1240.2	1240.25+1239.8	0.49
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	-29900.0%-29799.2pp	-100.8%	N/A	N/A	-97.3%
Return on Assets	-400.6%	N/A	N/A	-112.2%-70.9pp	-41.3%+72.2pp	-113.5%	N/A	-66.5%
Current Ratio	0.12-0.0	0.13-0.2	0.38	N/A	N/A	N/A	1.79-1.1	2.87
Debt-to-Equity	-1.28-0.0	-1.25+0.6	-1.85-267.4	265.50+264.1	1.44+9.2	-7.73-9.5	1.74+1.3	0.46
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$294K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.38), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Therma Bright Inc TBRIF

$2.8M

QHSLab Inc USAQ

$7.8M

Bionoid Pharma Inc BINP

$1.6M

Cyduct Diagnostics Inc CYDX

$3.3M

Kelyniam Global Inc KLYG

$5.5M

Frequently Asked Questions

What are Ir-Med Inc's total assets?

Ir-Med Inc (IRME) had $251K in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Ir-Med Inc spend on research and development?

Ir-Med Inc (IRME) invested $710K in research and development during fiscal year 2024.

How many shares does Ir-Med Inc have outstanding?

Ir-Med Inc (IRME) had 71M shares outstanding as of fiscal year 2024.

What is Ir-Med Inc's current ratio?

Ir-Med Inc (IRME) had a current ratio of 0.38 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Ir-Med Inc's debt-to-equity ratio?

Ir-Med Inc (IRME) had a debt-to-equity ratio of -1.85 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Ir-Med Inc's debt-to-equity ratio negative or unusual?

Ir-Med Inc (IRME) has negative shareholder equity of -$294K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Ir-Med Inc?

Ir-Med Inc (IRME) scores 11 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.